灯盏乙素
神经保护
医学
药理学
姜黄素
神经科学
体内
药代动力学
转化研究
帕金森病
临床前研究
作者
Yu Xiao,Xin-yue Li,Hui Ding,Jia-xin Wen,Yu-xiang Dai,Yu-jun Zhang,Shi-Pian Li,Yixuan Wang,Hao-jing Zhou,Bi-meng Zhang,Zhen-Yu Huang,Hong-Kan Lou,Yong-jun Wang,Xue-jun Cui,Hong-shen Wang,Min Yao
标识
DOI:10.1016/j.phrs.2026.109714
摘要
Neurodegenerative disorders are a leading cause of disability and mortality globally, but effective disease-modifying therapeutic strategies are still largely unavailable. Scutellarin is a flavonoid glycoside extracted from Erigeron breviscapus (Vant.) Hand-Mazz. It has been widely studied in preclinical models of neurodegenerative disorders. In this study, we performed a systematic review of preclinical animal studies. We combined comprehensive database retrieval with quantitative synthesis of eligible outcomes. The pooled results demonstrated that scutellarin significantly reduced cerebral infarct volume and improved neurological deficit scores in cerebral ischemia-reperfusion models. It also ameliorated learning and memory impairments in experimental Alzheimer's disease (AD) models. Consistent neuroprotective effects were also found in models of depression, anxiety, Parkinson's disease, etc. Mechanistic analysis indicated that scutellarin produces multi-level neuroprotective effects. It acts by reducing oxidative stress, inhibiting neuroinflammation, suppressing apoptosis, stabilizing the neurovascular unit and other neurobiological processes. This review first evaluated the preclinical efficacy of scutellarin through systematic review and meta-analysis. It then integrated cross-disease mechanisms with network pharmacology, reverse virtual screening and molecular docking to identify computationally predicted targets. Although scutellarin shows promising preclinical effects, its clinical translation faces major limitations. These limitations include low oral bioavailability, poor blood-brain barrier (BBB) penetration and insufficient data on brain exposure. Overall, scutellarin is a multi-target neuroprotective candidate. Future studies should focus on target validation, exposure-response modeling, delivery optimization and clinically relevant translational evaluation.
科研通智能强力驱动
Strongly Powered by AbleSci AI